至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.

PLoS ONE. 2013; 
NarayananRamesh,YepuruMuralimohan,CossChristopher C,WuZhongzhi,BaulerMatthew N,BarrettChristina M,MohlerMichael L,WangYun,KimJuhyun,SnyderLinda M,HeYali,LevyNelson,MillerDuane D,DaltonJam
Products/Services Used Details Operation
Custom Vector Construction … https://doi.org/10.1371/journal.pone.0083380. Editor: Irina U. Agoulnik, Florida International University, United States of America … FIG-ROS1 (S) [17], synthesized by Genscript (Piscataway, NJ), was cloned into pCMV6 vector and then sub-cloned into pLenti U6 Pgk-puro vector … Get A Quote

摘要

Receptor tyrosine kinases (RTKs), in response to their growth factor ligands, phosphorylate and activate downstream signals important for physiological development and pathological transformation. Increased expression, activating mutations and rearrangement fusions of RTKs lead to cancer, inflammation, pain, neurodegenerative diseases, and other disorders. Activation or over-expression of ALK, ROS1, TRK (A, B, and C), and RET are associated with oncogenic phenotypes of their respective tissues, making them attractive therapeutic targets. Cancer cDNA array studies demonstrated over-expression of TRK-A and ROS1 in a variety of cancers, compared to their respective normal tissue control... More

关键词